Noopept vs N-Acetyl Semax
Both compounds sit within the Russian cognitive-peptide research field but with substantially different compound architectures and clinical positioning. Noopept is a racetam-family dipeptide with an oral route and licensed Russian cognitive-support indication. N-Acetyl Semax is a derivative-analogue of Semax engineered for extended pharmacokinetic duration via N-terminal acetylation.
At a glance
| Noopept | N-Acetyl Semax | |
|---|---|---|
| Structural class | Racetam-family dipeptide (N-Phenylacetylprolylglycine ethyl ester) | N-terminally acetylated ACTH(4-10) analogue |
| Primary route | Oral | Intranasal |
| Parent / active moiety | Metabolises to CPG (cycloprolylglycine) active metabolite | Semax with N-terminal acetylation for extended half-life |
| Duration of action | Modest — active metabolite half-life determines effect window | Extended — the acetylation confers pharmacokinetic extension over parent Semax |
| Russian registration | Registered (Vidal.ru): tablets | Not assessed |
| Signature research application | Cognitive support, mild cognitive impairment research | Extended-duration Semax research applications |
| Evidence base | Substantial Russian clinical use, cognitive-endpoint studies | Less mature than parent Semax; positioned as PK-extended analogue |
| Evidence tier | B | C |
Compound-family positioning
Racetam-family versus Semax-family
Noopept sits within the racetam-family cognitive-support research space, but with the distinctive positioning of a peptide compound rather than a classical piracetam-family small molecule. The mechanism-of-action framing operates through the endogenous cycloprolylglycine (CPG) active metabolite, providing a mechanistic bridge between the racetam-family cognitive-support research heritage and the peptide-cognitive research field.
N-Acetyl Semax sits within the Semax-family cognitive-peptide research space as the extended-duration analogue of parent Semax. The N-terminal acetylation is a specific structural modification designed to reduce peptidase-mediated degradation and confer pharmacokinetic extension, allowing for less-frequent dosing and more consistent plasma-and-brain exposure than parent Semax.
This family-positioning difference has implications for research-tool selection. Noopept is well-suited to research designs that need racetam-family cognitive-support pharmacology in an oral-route format. N-Acetyl Semax is well-suited to research designs that need Semax pharmacology with reduced dosing frequency and more stable exposure profiles.
Practical usage considerations
Oral route versus intranasal route
Route-of-administration differences are substantial. Noopept's oral bioavailability makes it accessible for research applications that prioritise practical oral dosing. N-Acetyl Semax's intranasal route provides nose-to-brain delivery bypassing peripheral metabolism, which is a distinctive advantage for CNS-targeted research applications but requires research-context intranasal administration protocols.
For the specific comparison against parent Semax, N-Acetyl Semax offers the extended-duration advantage — dosing intervals can be extended, and plasma-and-brain exposure profiles are more stable across the dosing interval. This can be a research-tool advantage for chronic-effect research designs where dose-response consistency matters.
No entry for either compound was found in the electronic medicines compendium (emc) or on the EMA's list of centrally authorised medicines on 17 October 2026. For research applications the choice between them depends on the specific research question (racetam-family versus Semax-family pharmacology) and the practical constraints (oral versus intranasal administration; standard-duration versus extended-duration PK profile).